Characteristics of recurrent in-stent restenosis after second- and third-generation drug-eluting stent implantation

被引:4
|
作者
Shimono, Hirokazu [1 ]
Kajiya, Takashi [1 ]
Takaoka, Junichiro [1 ]
Miyamura, Akihiro [1 ]
Inoue, Takafumi [1 ]
Kitazono, Kazunari [1 ]
Ninomiya, Toshiko [1 ]
Atsuchi, Yoshihiko [1 ]
Atsuchi, Nobuhiko [1 ]
Ohishi, Mitsuru [2 ]
机构
[1] Tenyoukai Cent Hosp, Dept Cardiol, Izumi Cho 6-7, Kagoshima 8920822, Japan
[2] Kagoshima Univ, Dept Cardiovasc Med & Hypertens, Kagoshima, Japan
关键词
drug-eluting stent; in-stent restenosis; optical coherence tomography; OPTICAL COHERENCE TOMOGRAPHY; EX-VIVO ASSESSMENT; OUTCOMES; NEOATHEROSCLEROSIS; PATTERNS;
D O I
10.1097/MCA.0000000000000945
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In second- and third-generation drug-eluting stent (DES) era, in-stent restenosis (ISR) is not commonly seen. However, a few patients still need repeat revascularizations for recurrent ISR even after second- and third-generation DES implantation. Methods From January 2012 to March 2017, 2339 lesions underwent second- and third-generation DES (Nobori, Promus Element, Resolute Integrity, Xience, Ultimaster and Synergy) implantation, of which 95 lesions (4.1%) underwent revascularization for first ISR. All lesions were divided into two groups of recurrent ISR group and non-recurrent ISR group. After successful optical coherence tomography (OCT) guided revascularization for all lesions, we investigated characteristics of recurrent ISR, and 2 years follow-up were completed. Results The mean age was 70.8 +/- 11.7 years, and 73.2% were males. Among 56 DES-ISR lesions which were assessed by OCT, recurrent ISR was seen in 33.9% (N = 19) at 2 years follow-up after revascularization for first ISR. Serum low-density lipoprotein-cholesterol (LDL-C) level was higher in recurrent ISR group compared with non-recurrent ISR group (114.1 +/- 53.9 mg/dl vs. 90.9 +/- 27.8 mg/dl, P = 0.04) and heterogeneous tissue pattern was more frequently found in recurrent ISR group compared with non-recurrent ISR group (63.2% vs. 27.0%, P = 0.03). Multivariate analysis identified a heterogeneous tissue pattern (odds ratio 3.71; 95% confidence interval 1.09-12.59; P = 0.03) as an independent predictor of recurrent restenosis. Conclusion Recurrent ISR of second- and third-generation DES was associated with heterogeneous tissue pattern of first ISR, and high LDL-C level was associated with recurrence.
引用
收藏
页码:36 / 41
页数:6
相关论文
共 50 条
  • [41] Repeat drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent
    Cosgrave, John
    Melzi, Gloria
    Corbett, Simon
    Biondi-Zoccal, Giusseppe G.
    Babic, Race
    Airoldi, Flavio
    Chieffo, Alaide
    Sangiorgi, Giusseppe G.
    Montorfano, Matteo
    Michev, Iassen
    Carlino, Mauro
    Colombo, Antonio
    CIRCULATION, 2006, 114 (18) : 689 - 689
  • [43] Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent
    Ge, Heng
    Zhang, Qing
    Zhou, Wei
    He, Qing
    Han, Zhi-hua
    He, Ben
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2010, 11 (08): : 553 - 560
  • [44] Drug-eluting balloons for restenosis after stent implantation
    Alfonso, Fernando
    Perez-Vizcayno, Maria J.
    LANCET, 2013, 381 (9865): : 431 - 433
  • [45] OUTCOMES OF INTRAVASCULAR BRACHYTHERAPY IN RECURRENT DRUG-ELUTING IN-STENT RESTENOSIS
    Megaly, Michael
    Glogoza, Matthew
    Xenogiannis, Iosif
    Vemmou, Evangelia
    Nikolakopoulos, Ilias
    Willson, Laura
    Monyak, David J.
    Sullivan, Patsa
    Stanberry, Larissa
    Sorajja, Paul
    Chavez, Ivan
    Mooney, Michael R.
    Traverse, Jay
    Wang, Yale
    Garcia, Santiago
    Poulose, Anil
    Burke, M. Nicholas
    Brilakis, Emmanouil
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1151 - 1151
  • [46] Treating restenosis after drug-eluting stent implantation
    Megan Cully
    Nature Reviews Cardiology, 2013, 10 (2) : 62 - 62
  • [47] Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent
    Heng Ge
    Qing Zhang
    Wei Zhou
    Qing He
    Zhi-hua Han
    Ben He
    Journal of Zhejiang University SCIENCE B, 2010, 11 : 553 - 560
  • [48] Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis
    Megaly, Michael
    Glogoza, Matthew
    Xenogiannis, Iosif
    Vemmou, Evangelia
    Nikolakopoulos, Ilias
    Willson, Laura
    Monyak, David J.
    Sullivan, Patsa
    Stanberry, Larissa
    Sorajja, Paul
    Chavez, Ivan
    Mooney, Michael
    Traverse, Jay
    Wang, Yale
    Garcia, Santiago
    Poulose, Anil
    Burke, Martin Nicholas
    Brilakis, Emmanouil S.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2021, 97 (01) : 32 - 38
  • [49] Random forest vs. logistic regression: Predicting angiographic in-stent restenosis after second-generation drug-eluting stent implantation
    Jiang, Zhi
    Tian, Longhai
    Liu, Wei
    Song, Bo
    Xue, Chao
    Li, Tianzong
    Chen, Jin
    Wei, Fang
    PLOS ONE, 2022, 17 (05):
  • [50] Second- and third-generation drug-eluting coronary stents
    Akin, I.
    Schneider, H.
    Ince, H.
    Kische, S.
    Rehders, T. C.
    Chatterjee, T.
    Nienaber, C. A.
    HERZ, 2011, 36 (03) : 190 - 196